Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Accelerated hyperfractionated radiotherapy for malignant gliomas

J M Buatti1, R B Marcus, W M Mendenhall

  • 1Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida 32610-0385, USA.

International Journal of Radiation Oncology, Biology, Physics
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iron-based biomarkers for personalizing pharmacological ascorbate therapy in glioblastoma: insights from a phase 2 clinical trial.

Journal of neuro-oncology·2024
Same author

Magnetite nanoparticles as a kinetically favorable source of iron to enhance GBM response to chemoradiosensitization with pharmacological ascorbate.

Redox biology·2023
Same author

Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients.

Redox biology·2023
Same author

Design and characterization of a prototype tertiary device for proton beam stereotactic radiosurgery.

Biomedical physics & engineering express·2021
Same author

Proton vs Hyperarc™ radiosurgery: A planning comparison.

Journal of applied clinical medical physics·2020
Same author

Novel MRI and CT compatible stereotactic brain biopsy system in dogs using patient-specific facemasks.

The Journal of small animal practice·2017

Accelerated hyperfractionated radiotherapy for malignant gliomas is well-tolerated and shows improved progression-free survival compared to standard treatments. This approach is a promising option for future clinical trials in neuro-oncology.

Area of Science:

  • Neuro-oncology
  • Radiation Oncology

Background:

  • Malignant gliomas are aggressive brain tumors with limited treatment options.
  • Standard radiotherapy fractionation regimens have associated toxicities and progression rates.

Purpose of the Study:

  • To evaluate the efficacy and safety of accelerated hyperfractionated radiotherapy (AH-RT) for treating malignant gliomas.

Main Methods:

  • A cohort of 68 adult patients with malignant gliomas received AH-RT (1.5 Gy twice daily to 60 Gy).
  • Some patients received stereotactic radiosurgery boosts.
  • Median follow-up was 6 months.

Main Results:

  • Median survival was 13.8 months, with 2-year and 5-year survival rates of 16% and 4%, respectively.

Related Experiment Videos

  • High Karnofsky performance status, boost therapy, and surgical excision were associated with improved outcomes.
  • AH-RT was well-tolerated, with low rates of severe toxicity and progression during treatment.

    • Conclusions:

    • Accelerated hyperfractionated radiotherapy is a safe and effective treatment for malignant gliomas.
    • This regimen demonstrates a significantly lower rate of disease progression during treatment compared to standard fractionation.
    • AH-RT offers potential advantages and serves as a basis for further clinical investigation.